>Ahem< that should be
non-muscle-invasive bladder cancer
Anticancer Activity of Metallodrugs and Metallizing Host Defense Peptides—Current Developments in Structure-Activity Relationship ....The TLD-1433 complex, described by S. McFarland’s research group, 2020, is the first Ru(II)-based photosensitiser for photodynamic therapy to enter human clinical trials for the treatment of muscle-invasive bladder cancer [186]. This complex has two 4,4’-dimethyl-2,2’-bipyridine ligands and an imidazole [4,5-f]-1,10-phenanthroline ligand substituted with three thiophene rings. The activation of this complex consists of the loss of a ligand, photoinduced by visible light in water (Figure 36), activating the complex by forming covalent bonds with guanosine monophosphate, through the substitution of labile Ru-OH2.
Figure 36. Molecular structure of the PS complex of Ru(II) TLD4133. Activation of the TLD-1433 complex.
From the study with TLD1433, new Ru(II) complexes were developed for use in PDT, (Figure 37). Chao’s research group developed the polypyridyl Ru(II) complex containing a triphenylphosphonium (A) substituent to target the compound to mitochondria [187]. It is active in two-photon PDT.